200 likes | 450 Views
Ipilimumab Versus Placebo After <br />Complete Resection of Stage III Melanoma: <br />Initial Efficacy and Safety Results from the EORTC 18071 Phase III Trial. Presented By Alexander Eggermont at 2014 ASCO Annual Meeting. Slide 2. Presented By Alexander Eggermont at 2014 ASCO Annual Meeting.
E N D
Ipilimumab Versus Placebo After <br />Complete Resection of Stage III Melanoma: <br />Initial Efficacy and Safety Results from the EORTC 18071 Phase III Trial Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Slide 2 Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Slide 3 Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Immune Checkpoint Inhibitor Ipilimumab Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
EORTC 18071/CA184-029: Study Design Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Key Eligibility Criteria Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Slide 7 Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Baseline Patient Characteristics Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Primary Endpoint: Recurrence-free Survival (IRC) Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Recurrence-free Survival: Prespecified Subgroups Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Slide 11 Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Slide 12 Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Time to Onset of Grade 2-5 irAEs Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Slide 14 Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Slide 15 Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Subgroup Analyses of RFS: Microscopic (N1) vs Clinically Palpable (N2) Lymph Nodes Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Summary/Conclusions Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Acknowledgments Presented By Alexander Eggermont at 2014 ASCO Annual Meeting